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A and—much slower—B from the N ‑termini of 
the Aα and Bβ chains, respectively, resulting in 
the formation of fibrin monomer with exposed 
binding sites in the E domain. Fibrin monomers 
polymerize via noncovalent interactions between 
the D and E domains with subsequent lateral ag‑
gregation promoted mainly by intermolecular 
cross ‑linking of α chains and probably by interac‑
tions between α and γ chains.3,4 A half ‑staggered 
fibrin structure forms a protofibril.
Fibrin resistance to plasmin degradation is de‑
termined largely by covalent cross ‑linking medi‑
ated by activated factor XIII (FXIII), a transgluta‑
minase enzyme whose formation from zymogen 
FXIII is catalyzed by thrombin. Active FXIII cat‑
alyzes the formation of covalent bonds between 
γ ‑γ, γ ‑α, and α ‑α chains of contiguous fibrin poly‑
peptide chains.5 FXIII also links α2 ‑antiplasmin 
and plasminogen activator inhibitors to fibrin to 
ensure clot resistance to enzymatic degradation.5 
Fibrinogen and fibrin specifically bind a variety 
Fibrin formation and structure Fibrin is the main 
protein component of a blood clot and intravas‑
cular thrombi in all locations. Efficient fibrin for‑
mation and its normal functions are essential for 
hemostasis.1 Fibrinogen, the soluble fibrin precur‑
sor synthesized in the liver, is a 340 ‑kDa glyco‑
protein composed of 3 paired polypeptide chains 
(AαBβγ)2 that are cross ‑linked together by 29 di‑
sulfide bonds. Fibrinogen contains 3 main struc‑
tural regions connected by α ‑helical coils: a cen‑
tral E domain composed of the N ‑termini of all 6 
polypeptide chains and 2 outer D domains with 
C ‑termini of the Bβ and γ chains. The C ‑termi‑
nal of the Aα chain is a globular structure locat‑
ed near the central E domain. Approximately 10% 
of total plasma fibrinogen molecules contain γ’ 
chain, whose presence may contribute to cardio‑
vascular disease.1-3
Fibrin formation is initiated by thrombin 
cleavage of the Aα and Bβ chains of fibrinogen.3 
Thrombin specifically cleaves fibrinopeptides 
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AbsTRACT
Fibrin formed as a result of fibrinogen polymerization is the main protein component of a clot in a test 
tube and intravascular thrombi in vivo. Fibrin clot structure characterized by fiber diameter and pore size 
differs between healthy persons and those with thromboembolic diseases, in part due to the quality and 
quantity of fibrinogen and the magnitude of thrombin generation. A key measure of plasma clot structure is 
its permeability, reflected by the Darcy constant (Ks). Reduced Ks is a typical feature of the prothrombotic 
fibrin clot phenotype, which is associated with faster formation of denser fibrin mesh, relatively resistant 
to lysis. Low Ks has been reported in patients with prior or acute myocardial infarction (MI), stroke, or 
venous thromboembolism (encompassing deep vein thrombosis [DVT] and pulmonary embolism [PE]), as 
well as in those with prothrombotic conditions (eg, in several thrombophilic states) and in the presence 
of cardiovascular risk factors (eg, obesity). Antithrombotic and anticoagulant agents, along with statins, 
have been shown to increase Ks. Growing evidence indicates associations between the properties of 
plasma fibrin clots and morphology of intravascular thrombi in patients with MI. Recently, reduced Ks 
has been shown to predict recurrent thromboembolic episodes in patients with a history of stroke, PE, 
DVT, and their serious complications, including postthrombotic syndrome and thromboembolic pulmonary 
hypertension. We discuss the current evidence for the significance of clot density measured in vitro as 
a prognostic marker in a number of clinical conditions associated with elevated thromboembolic risk.
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Clot compaction is a measure of fibrin density, 
thus indirectly clot permeability. After clot forma‑
tion, samples are centrifuged at 6000 to 8000 × g 
for usually 60 seconds and the volume of the su‑
pernatant evacuated from tubes is assessed as 
a difference in tube weight. Finally, clot compac‑
tion is expressed as a volume of the supernatant 
divided by the initial plasma volume used to form 
the clot. A normal clot compaction is about 60% 
to 70% using this technique. Less compact clots 
(usually about 40%) are associated with impaired 
clot lysis due to impaired transport of proteolyt‑
ic enzymes through the fibrin network.
Fibrin formation in purified systems as well as 
in plasma are assessed by turbidimetry. The pa‑
rameters used are the lag phase that reflects 
the time to the start of lateral fibril aggregation, 
the maximum absorbance of the growing clot that 
reflects an average fibrin fiber size and the num‑
ber of protofibrils per fiber, and the rate of ab‑
sorbance increase (FIguRE 1b).10,11
The most commonly used imaging techniques 
for visualization of fibrin clot structure include 
scanning or transmission electron microscopy, 
along with confocal microscopy.10 Scanning elec‑
tron microscopy allows a measurement of the fi‑
ber diameter, pore size, and branching angles. 
However, this technique requires a clot fixation 
with glutaraldehyde solution followed by its de‑
hydration. Physiologically, fibrinogen undergoes 
many posttranslational modifications, thus puri‑
fied models compared with plasma ‑based mod‑
els can mimic the in vivo situation. Fibrin clot 
formed from a citrated plasma is characterized by 
2 to 4 times thicker fibers and larger pores com‑
pared with a clot formed from purified fibrinogen 
at similar protein levels.12 Fibrinogen is known 
as the main determinant of fibrin clot structure; 
however, variation in its levels explained only 
18% of the variation in Ks and 48% of the varia‑
tion in maximum absorbance in turbidimetry.13 
of other proteins, including albumin, apolipopro‑
teins, complement C3, ferritin, fibronectin, fib‑
ulin, fibroblast growth factor 2, haptoglobin, in‑
terleukin 1β, myosin, plasminogen, thrombos‑
pondin, histidine‑rich glycoprotein, vitronectin, 
vascular endothelial growth factor, and von Wil‑
lebrand factor.6
Mechanical properties of fibrin The structure of fi‑
brin and its resistance to mechanical deformation 
and/or enzymatic degradation are essential for fi‑
brin functions and depend on fibers’ architecture 
and their individual properties.1,3 At the level of 
the individual fibrin monomers, the coiled ‑coil 
connectors, folded globular nodules, and αC re‑
gions largely contribute to the fibrin clot mechan‑
ics.7 Fibrin networks have 1.5 ‑to 3 ‑fold lower ex‑
tensibilities than individual fibers, thus clot deg‑
radation after extension is limited to the branch 
points rather than single fibers.8 Fibrin fibers are 
composed of thousands of twisted protofibrils ar‑
ranged side by side with a periodicity of 22.5 nm.9 
Extremely durable cross ‑linked fibrin fibers can be 
strained over 6 times their length and they have 
the largest extensibilities among fiber proteins.8
Assessment of fibrin properties The architecture 
of a fibrin clot can be characterized by the fiber 
diameter and the size of the pores in the fibrin 
network. Fibrin porosity is typically estimat‑
ed using a clot permeability under different hy‑
drostatic pressures in a few assays of varying re‑
agents and their concentrations.10 Clot permea‑
bility is calculated based on the volume of a buf‑
fer flowing through a fibrin gel in a given time 
period using the Darcy constant: Ks (×10
 –9 cm2) = 
Q×L×η/t×A×Δp, where Q is the volume (in ml) of 
liquid passed through in time t, η is the viscosity 
of the fluid (in poise), L is the length of the gel 
(in cm), A is a cross ‑sectional area (in cm2), and 
p is the applied pressure (in dyne/cm2) (FIguRE 1A).
FIguRE 1 A – schematic presentation of the system used to assess fibrin clot porosity by measuring its permeability under a hydrostatic pressure 
using the clot permeability formula; b – turbidimetric measurement of fibrin clot formation following addition of calcium and thrombin to plasma  
Abbreviations: A, cross ‑sectional area; Abs, absorbance; L, clot length; Q, volume of the fluid; Δp, differential pressure
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around 10% or less) and universal standards to en‑
sure acceptable between ‑laboratory variability.20
This review will focus on reduced fibrin clot 
permeability, which represents the so ‑called pro‑
thrombotic fibrin clot phenotype in patients with 
thromboembolic disorders, in particular on myo‑
cardial infarction (MI), stroke, and venous throm‑
boembolism (VTE), including pulmonary embo‑
lism (PE) and deep vein thrombosis (DVT). Clini‑
cal conditions associated with reduced fibrin clot 
permeability are shown in FIguRE 2.
Fibrin clot phenotype in myocardial infarction 
Acute coronary artery thrombus formation as‑
sociated mostly with atherosclerotic plaque rup‑
ture results in a blood flow cessation in an infarct‑
‑related artery area, leading to ST ‑segment ele‑
vation MI (STEMI). Scanning electron micros‑
copy of intracoronary thrombi from patients 
with STEMI showed that thrombus composition 
evolves over time during the acute phase of MI 
and fibrin content increased from 31% to 78%.25 
Fibrin, erythrocyte, platelet, and white blood cell 
content in the thrombi were estimated at 49.1%, 
24.2%, 11.6%, and 3.7%, respectively.25 Interest‑
ingly, higher content of fibrin (61.6% vs 34.3%) 
and platelets (8.2% vs 4.8%) and lower erythro‑
cyte content (15.8% vs 42.9%) were found on the 
intracoronary thrombus surface compared with 
its inner part.26 In patients with acute MI before 
percutaneous coronary intervention (PCI), fi‑
brinogen, P ‑selectin, and plasminogen activator 
At low concentrations of fibrinogen, clots are 
composed of thicker fibers, while clots formed 
at higher concentrations of fibrinogen are com‑
posed of thinner fibers. Clot structure also de‑
pends on the conditions during fibrinogen po‑
lymerization.2 Increased thrombin concentra‑
tions in a dose ‑dependent manner result in fast‑
er formation of thinner fibrin fibers with small‑
er pores.14 Thus, higher thrombin generation is 
directly associated with lower clot permeabili‑
ty. Elevated FXIII activity has also been shown 
to affect clot structure by increasing its stabili‑
ty.15 Generally, fibrin clots are composed of thin‑
ner fibers and smaller pores and are more com‑
pact and less permeable, while those with thick‑
er fibers are more permeable and susceptible for 
fibrinolysis.16,17
In 1977, Carr et al18 estimated for the first time 
the clot permeability by measuring the buffer flow 
through a fibrin gel. Currently, several methods 
and models are used to determine fibrin porosi‑
ty, including those in which clotting is initiated 
by thrombin or tissue factor in platelet ‑poor or 
platelet ‑rich plasma, using manual or semiauto‑
mated techniques.19-23 In 2012, the Factor XIII 
and Fibrinogen Subcommittee of the Scientif‑
ic and Standardisation Committee of the Inter‑
national Society on Thrombosis and Haemosta‑
sis published the first recommended protocol for 
Ks measurement.
24 Regardless of the assay used, 
Ks measurement requires much hands ‑on expe‑
rience to obtain reproducible results (variability 
FIguRE 2 Clinical conditions in which prothrombotic fibrin clot phenotype has been reported  
Abbreviations: AAA, abdominal aortic aneurysm; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CTEPH, chronic 
thromboembolic pulmonary hypertension
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of the blocked coronary artery. A small prospec‑
tive study demonstrated an increased risk of ar‑
terial thrombotic events associated with reduced 
Ks and prolonged lysis time in patients on long‑
‑term hemodialysis.38
Altered fibrin clot structure and function ob‑
served in MI is largely determined by factors asso‑
ciated with increased oxidative stress and throm‑
bin generation, along with prothrombotic actions 
of platelet ‑derived proteins (eg, platelet factor 4 
or β ‑thromboglobulin).11,26,28,39 Hyperglycemia, 
observed in up to 50% of the patients with acute 
MI, impaired clot susceptibility to lysis but had no 
effect on Ks.
40 On the other hand, patients with 
type 2 diabetes presented impaired clot struc‑
ture, including its reduced Ks, associated with 
prolonged duration of diabetes.41 This observa‑
tion underlines the role of prothrombotic mem‑
ory in the pathogenesis and risk assessment of 
thrombotic events.41 Interestingly, cellular fibro‑
nectin, a marker of vascular injury, was increased 
and associated with altered fibrin clot properties 
in patients with type 2 diabetes and concomitant 
cardiovascular disease but not in patients with‑
out cardiovascular disease, suggesting a direct link 
between blood vessel damage and prothrombot‑
ic clot phenotype.42
Increased oxidative stress, platelet activation, 
and thrombin generation play a key role in the 
pathogenesis of MI. Growing evidence indicates 
that clots formed in the presence of oxidants and 
high thrombin concentrations are compact, com‑
posed of thin fibers, and have reduced Ks.
30,43,44 
Thus, fibrin clot porosity is a promising prognos‑
tic marker in patients with MI.
Fibrin clot phenotype in stroke Precerebral or ce‑
rebral artery occlusions constitute a major per‑
centage of all acute strokes. Thrombi retrieved 
from the cerebral arteries of patients with acute 
ischemic stroke contained fibrin and platelet de‑
posits, together with erythrocyte components.45 
Fibrin content in thrombi obtained from 50 pa‑
tients with acute middle cerebral artery ischemic 
stroke was 61%, and fibrin ‑rich thrombus oc‑
curred most commonly among these patients.46 
Acute ischemic stroke within the first 72 hours of 
symptom onset was associated with Ks reduced by 
30% as compared with healthy controls.47 
Fibrin properties showed an association with 
stroke severity but not with mortality during 
long ‑term follow ‑up.48 Fibrin clot compaction 
correlated with neurological deficit both on ad‑
mission and at discharge of patients admitted 
for acute ischemic stroke.47 Formation of dens‑
er fibrin clots displaying impaired lysability and 
pattern of their changes induced by thromboly‑
sis may affect clinical outcome in patients with 
acute ischemic stroke.49 We have reported recent‑
ly that in stroke patients eligible for recombinant 
tissue plasminogen activator (rtPA) treatment, 
fibrin networks assessed 24 hours since throm‑
bolysis were 37% less compact and lysed 21% 
more rapidly compared with the pretreatment 
inhibitor 1 (PAI ‑1) were positively correlated with 
thrombus fibrin content.25 Diminished clot per‑
meability in 40 patients with acute MI was relat‑
ed to the degree of oxidative stress and inflam‑
mation.27 Different oxidative modifications of fi‑
brinogen molecule were associated with various 
changes in the clot structure and function.28-31 
Serum F2 ‑isoprostanes produced upon nonen‑
zymatic arachidonic acid peroxidation, as well 
as platelet activation reflected by the concentra‑
tions of β ‑thromboglobulin, have been shown 
to correlate with Ks in patients with acute MI.
29
Zalewski et al26 showed for the first time that 
fibrin content in the intracoronary thrombi ob‑
tained from patients with acute MI was inverse‑
ly correlated with Ks, and the latter variable inde‑
pendently predicted fibrin content in the whole 
thrombus. This indicates that plasma clot features 
affect thrombi formed in the vessels, which sup‑
ports the value of plasma clot analysis in the pre‑
diction of in vivo thrombus composition.
The presence and amount of the proteins with‑
in a plasma clot also influence clot properties.11 
Using a shotgun proteomic method to investigate 
time ‑dependent protein composition of clots pre‑
pared ex vivo from citrated plasma obtained from 
patients with acute MI, 62 proteins were identi‑
fied in all 8 samples grouping into several dis‑
tinct functional clusters (eg, cholesterol trans‑
porter activity, immunoglobulin binding, and 
peptidase regulatory activity).32 The protein sig‑
natures of clots differed significantly depending 
on time after acute coronary syndrome, showing 
30% greater variability in protein composition of 
the plasma clots generated 2 months after the on‑
set of acute MI.32 Differences involving proteins 
of potential influence on within ‑clot fibrinoly‑
sis (ie, α2 ‑antiplasmin) may at least in part ex‑
plain time ‑dependent changes in the clot struc‑
ture in patients with acute MI.32 Before PCI, fi‑
brinogen, P ‑selectin, and PAI ‑1 levels were pos‑
itively correlated with thrombus fibrin content, 
while after PCI, von Willebrand factor antigen, 
soluble CD40 ligand, and myeloperoxidase were 
associated with thrombus fibrin content.25 Af‑
ter adjustment for fibrinogen and the onset ‑to‑
‑thrombectomy time, circulating von Willebrand 
factor antigen was the independent predictor of 
fibrin ‑rich intracoronary thrombi.25
Reduced clot permeability by about 30% has 
been reported for the first time in men with a his‑
tory of premature MI.33 Thus, thrombotic disor‑
ders can be attributed to more compact and less 
permeable fibrin structure.34 MI in the past has 
also been linked with the prothrombotic fibrin 
clot phenotype in young patients.35 Interesting‑
ly, first ‑degree male relatives of patients with 
premature coronary artery disease had less per‑
meable clots than controls.19 Reduced clot per‑
meability by 21% and 18%, respectively, charac‑
terized also patients with in ‑stent thrombosis36 
and patients with a history of the no ‑reflow phe‑
nomenon,37 defined as the absence of a complete 
myocardial perfusion despite successful opening 
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earlier, were less permeable and were lysed fast‑
er compared with those with VTE alone.57 This 
study showed for the first time that antiphos‑
pholipid syndrome is associated with the pro‑
thrombotic plasma fibrin clot phenotype, with 
even worse characteristics in patients following 
arterial thrombosis, largely stroke.57
Overall, ischemic stroke is linked with pro‑
thrombotic alterations in fibrin structure and 
function, indicating common mechanisms lead‑
ing to cerebrovascular and coronary thromboem‑
bolic episodes.11,34
Fibrin clot phenotype in venous thromboembo-
lism The pathogenesis of VTE, encompassing 
DVT and PE, is multifactorial with about 50% of 
patients suffering from unprovoked (formerly id‑
iopathic) episodes. Thrombotic material removed 
from the pulmonary arteries in acute PE showed 
that the main component of the thrombus is fi‑
brin.58,59 Interestingly, thrombi located in the dis‑
tal arteries were richer in fibrin and contained 
fewer erythrocytes than those from the proxi‑
mal arteries.58 Martinez et al60 showed that clot 
structure and functional properties, including clot 
formation, lysis, and viscoelastic properties, dif‑
ferentiated patients with acute DVT from those 
with PE, suggesting that lower fiber density and 
faster lysis in patients with PE may affect embo‑
lization. Less compact fibrin structure associat‑
ed with faster clot lysis seems to characterize pa‑
tients who experienced PE, regardless of the pres‑
ence of concomitant DVT.61 It might be speculated 
that higher Ks combined with shorter lysis time, 
found in patients with PE compared with DVT, 
contributes to clot fragmentation and the sub‑
sequent embolization.61 Recently published com‑
putational model simulations describing interac‑
tions between main clot components under shear 
flow suggest that blood clots with higher clot shell 
permeability are more prone to embolization un‑
der increasing shear rate.62
It has been reported that some environmen‑
tal factors affect fibrin clot structure in patients 
with DVT. Long ‑term exposure to particulate mat‑
ter with a diameter of less than 10 μm (PM10) has 
been associated with a denser fibrin network with 
Ks decreased by 22% in 103 patients with DVT 
but not in controls, suggesting an increased risk 
of recurrent episodes in patients predisposed to 
venous thrombosis.63
Siudut et al64 showed that also cerebral venous 
sinus thrombosis (CVST), which is a rare form 
of VTE, can be associated with the formation of 
more compact plasma fibrin clots and resistance 
to fibrinolysis. Ks was 12% lower in 50 patients 
with CVST (mean [SD] age, 38.9 [9.8] years) after 
the event unrelated to trauma or malignancy fol‑
lowing anticoagulation withdrawal, as compared 
with controls.64 Importantly, recurrent CVST dur‑
ing follow ‑up was associated with 21% higher 
baseline fibrinogen levels and 20% lower Ks,
64 
which suggest a predictive value of this fibrin clot 
structure measure (FIguRE 3).
values.49 Moreover, thrombolysis with rtPA within 
4.5 hours since stroke onset markedly attenuat‑
ed thrombin generation, including reduced max‑
imal thrombin concentrations, measured at 24 
hours with a large contribution of activated fac‑
tor XI which was found in about 15% of patients.50
Patients who survived ischemic stroke have 
also been characterized by abnormal plasma fi‑
brin clot properties. The first report showing pro‑
thrombotic clot abnormalities was published for 
patients with cryptogenic stroke and evidenced 
more compact plasma clots generated in vitro 
with an increased fiber diameter and density.51 
The prothrombotic fibrin clot phenotype, includ‑
ing Ks reduced by 7.5% and lysis time prolonged 
by 13.8%, characterized patients with prior isch‑
emic stroke.52
Reduced Ks observed within the first 24 hours 
since the onset of stroke symptoms in nonthrom‑
bolysed patients remained unaltered after 60 days 
from the event, suggesting that the prothrom‑
botic clot phenotype is a persistent feature of pa‑
tients suffering from ischemic stroke.53
The worse prognosis is observed in patients 
with atrial fibrillation (AF) who experienced acute 
cerebrovascular episode. Since 15% of ischemic 
strokes occur in patients with AF and they are 
mostly caused by thrombotic material formed 
within the left atrium, precisely in 90% in its ap‑
pendage, the prothrombotic fibrin clot phenotype 
might also increase the risk of cerebral infarction. 
It has been shown that formation of compact 
plasma fibrin clots resistant to lysis is observed 
in patients with different types of AF,54 and those 
unfavorable fibrin properties can at least in part 
determine the efficacy and safety of anticoagu‑
lation with vitamin K antagonists.55 Interesting‑
ly, patients with lower Ks (<6.8 × 10
 –9 cm2) had in‑
creased risk of ischemic stroke or transient isch‑
emic attack (hazard ratio [HR], 6.55; 95% confi‑
dence interval [CI], 2.17–19.82) and major bleeds 
(HR, 10.65; 95% CI, 3.52–32.22), while patients 
with elevated Ks (≥6.8 × 10
 –9 cm2) had an increased 
rate of minor bleeding compared with the remain‑
der (11.63% per year vs 3.55% per year).55 Inter‑
estingly, in 160 patients with AF, prothrombotic 
fibrin clot properties were determined by PAI ‑1 
and N ‑terminal pro ‑B‑type natriuretic peptide 
associated with long ‑term prognosis.52
Prothrombotic blood alterations could be also 
involved in the left atrial appendage thrombus 
formation in patients without documented AF 
and are associated with increased risk of stroke or 
transient ischemic attack.56 Ks reduced by 1 unit 
was shown to be associated with 5 ‑fold higher 
odds of recurrent left atrial appendage thrombus 
during follow ‑up, which suggests that clot fea‑
tures persist over time and might have a prognos‑
tic value.56 Fibrin clot features could be involved 
in an increased stroke risk also in specific patient 
populations, including those with acquired throm‑
bophilia. We found that plasma fibrin clots from 
patients with antiphospholipid syndrome, who 
experienced stroke and/or MI at least 5 months 
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easier to achieve with new oral anticoagulants 
available worldwide.
Patients with residual vein obstruction, detect‑
ed in up to 50% of patients following DVT, were 
also characterized by 14% lower Ks related to el‑
evated lipoprotein(a) and overrepresentation of 
its smaller isoforms.68
Chronic thromboembolic pulmonary hyperten‑
sion (CTEPH), a severe PE complication, is asso‑
ciated with changes in fibrinogen molecule struc‑
ture and/or function followed by altered proper‑
ties of the clot formed from modified protein.69 
This might result in the development of CTEPH 
by prolonged fibrin clot presence within the pul‑
monary arteries and remodeling of the throm‑
bi into fibrotic layer. Patients with CTEPH have 
a relatively high incidence of inherited dysfibrin‑
ogenemias in which abnormal fibrin clot pheno‑
type occurs,70,71 suggesting that clot properties 
may lead to identification of patients at risk of 
this complication and might be helpful in deter‑
mining the efficacy of therapy.72
Looking at genetic thrombophilias attributed 
to VTE, fibrin abnormalities have also been re‑
ported. The prothrombin G20210A mutation in 
patients after VTE has been shown to be linked 
with unfavorable fibrin clot characteristics, in‑
cluding 12% lower Ks, compared with noncarri‑
ers.73 Rivaroxaban treatment improved fibrin clot 
properties in carriers and noncarriers of the pro‑
thrombin G20210A mutation, but anticoagu‑
lant therapy cannot abolish more prothrombot‑
ic fibrin clot phenotype observed in prothrom‑
bin mutation carriers following VTE.73 Factor V 
(FV) Leiden mutation is observed in 3% to 15% 
of the white population and in 15% to 30% of pa‑
tients with VTE.74 In thrombosis ‑free heterozy‑
gous carriers of FV Leiden mutation, Ks was slight‑
ly reduced compared with noncarriers.74
Recent data indeed indicate that plasma clot 
characteristics might identify patients at high 
risk of recurrent VTE. In 2017, we observed 
that recurrent PE, diagnosed during follow ‑up 
in 23 patients (5% per year) following the first‑
‑ever provoked or unprovoked PE, is associat‑
ed with formation of denser fibrin networks, 
as evidenced by reduced Ks (HR, 1.82; 95% CI, 
1.01–3.13; FIguRE 3).65
Postthrombotic syndrome is a common com‑
plication of DVT that has been found to be asso‑
ciated with Ks reduced by 11.7% when assessed 
3 months after the index DVT.66 Recurrent VTE 
occurred also more commonly in patients with 
postthrombotic syndrome, who were character‑
ized by lower Ks and prolonged clot lysis time 
(CLT).66
Very recently, we have published convinc‑
ing evidence for the predictive value of the pro‑
thrombotic clot phenotype in patients with DVT. 
Among 320 consecutive patients after the first‑
‑ever DVT, recurrences were observed in 25% 
of the patients (6.6% per year) during a median 
follow ‑up of 44 months. Recurrent DVT was as‑
sociated with denser fibrin networks (12% low‑
er Ks), and reduced Ks was an independent pre‑
dictor of recurrences.67 The risk of recurrent 
DVT increased 15 ‑fold (95% CI, 7.5–33.5) in pa‑
tients with low Ks (≤7.3 × 10
 –9 cm2) combined with 
prolonged CLT (>96 min).67 Interestingly, fibrin 
properties analyzed as single measures were less 
effective as DVT predictors when compared with 
the combined analysis of Ks and CLT (FIguRE 3).
67
This work encourages efforts to develop user‑
‑friendly assays to test clot properties in practice 
to improve identification of patients with VTE 
at risk of recurrent episodes following anticoag‑
ulation cessation. The prothrombotic clot phe‑
notype could be a factor which renders the pa‑
tient suitable for long ‑term anticoagulation, now 
FIguRE 3 Relative differences in plasma fibrin clot permeability (ΔKs) measured after 3 to 6 months since the index 
event between patients who experienced recurrent venous thromboembolic (VTE) episodes, including cerebral venous 
sinus thrombosis (CVST), deep vein thrombosis (DVT), and pulmonary embolism (PE) during a few years’ follow ‑up 
versus those free of such events in the respective studies.64,65,67 Ks for patients without recurrent VTE is marked on the 
top of the vertical line. 
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by 36% to 91% at therapeutic plasma concen‑
tration.83 In the same model, warfarin at plasma 
concentration adjusted to obtain the therapeu‑
tic range (international normalized ratio, 2–3) 
resulted in an Ks increase of about 35%. Warfa‑
rin and acenocoumarol as vitamin K antagonists 
have been shown to increase Ks in patients with 
AF as early as after 3 days of treatment, reaching 
the plateau value after 7 days.81 Those favorable 
changes in clot structure were strictly associat‑
ed with diminished activities of vitamin K ‑depen‑
dent clotting factors and lower protein C activity, 
resulting in lower thrombin generation. Rivarox‑
aban, a non –vitamin K antagonist oral anticoag‑
ulant and direct Xa inhibitor, at 2 to 6 hours after 
intake improved Ks by 37% in patients with pre‑
vious VTE.73 Interestingly, after 20 to 25 hours 
since rivaroxaban intake, clot permeability re‑
turned to the baseline value.73
Statins also produce fibrin modulatory effects. 
Atorvastatin, beside its role as a  cholesterol‑
‑lowering agent, has also antithrombotic properties 
in VTE patients, observed as favorable alterations 
in fibrin clot phenotype, in particular Ks reduced 
by 23% after statin use for 3 days.84 Furthermore, 
anticoagulant effects of statins have been related 
to a decreased tissue factor expression followed by 
reduced thrombin generation, attenuation of pro‑
coagulant reactions catalyzed by thrombin, such as 
fibrinogen cleavage, FV and FXIII activation, and 
enhanced endothelial thrombomodulin expression, 
resulting in increased protein C activation and in‑
activation of activated FV.85 A 3 ‑month simvastatin 
treatment increased Ks in patients without history 
of cardiovascular events and low density lipopro‑
tein cholesterol of less than 3.4 mmol/l.86 Benefi‑
cial effects of simvastatin treatment on Ks (an in‑
crease of 16%), irrespective of cholesterol reduction, 
were also seen in patients with chronic obstructive 
pulmonary disease.87 These findings provide evi‑
dence that fibrin clot modulation contributes to 
antithrombotic effects of statins, which explains 
at least in part a reduced VTE risk in statin users 
observed in several studies.
Practical implications There are several limita‑
tions to assess fibrin clot properties in clinical 
practice. The availability of fibrin measures is 
limited to a few specialized laboratories. Due to 
Among modifiable VTE risk factors, oral con‑
traceptives have been shown to unfavorably al‑
ter plasma clot characteristics.74 Discontinuation 
of oral contraceptives was associated with short‑
ened lysis time and increased Ks.
74
It is known that obesity is associated with 
an increased risk of thromboembolic events. In‑
terestingly, in 29 obese patients studied before 
and after 3 ‑month low ‑fat diet, which resulted 
in the reduction of body weight and the levels of 
total cholesterol, low ‑density lipoprotein choles‑
terol, triglycerides, and PAI ‑1, was also associat‑
ed with increased clot potential to lysis, while Ks 
remained unchanged.75
Taken together, there is evidence that a num‑
ber of thrombosis risk factors, both genetical‑
ly determined and acquired, are associated with 
denser plasma clot structure, which might con‑
tribute to their effects reaching beyond the im‑
pact of increased thrombin generation.
Antithrombotic agents and fibrin clots Growing ev‑
idence indicates a strong impact of several anti‑
thrombotic, cholesterol ‑lowering, or antihyper‑
tensive agents on fibrin clot structure (TAbLE 1). 
Administration of low ‑dose aspirin was shown to 
be associated with improved clot properties large‑
ly through fibrinogen acetylation.76,77 Fibrinogen 
is acetylated at several lysine residues, which also 
are involved in the FXIII ‑mediated cross linking 
of fibrin.77 In vivo, aspirin concentration of 37.5, 
320, and 640 mg/d increased Ks by 44%, 31%, and 
21%, respectively, and treatment with low ‑dose 
aspirin led to formation of thicker fibrin fibers 
with larger pores.78 Similar effects of low ‑dose 
aspirin were seen in patients with coronary ar‑
tery disease and in those with VTE.79 Moreover, 
1 week after aspirin withdrawal, Ks returned to 
the baseline value.79
The impact of several other antithrombotic 
drugs on fibrin clot structure and function was 
determined by the influence on clotting factors 
and/or reduced thrombin generation.80,81 Direct 
and indirect thrombin inhibitors, including arg‑
atroban, bivalirudin, and danaparoid, have been 
shown to increase Ks at therapeutic concentra‑
tions in in vitro models to a similar extent.82
Direct thrombin and factor Xa inhibitors add‑
ed in vitro to normal plasma also increased Ks 
TAbLE 1 Medications reported to alter fibrin clot permeability
Medication Mode of action: suggested change in
Metformin Glycation of fibrinogen and plasminogen; inflammatory state
Insulin Glycation of fibrinogen and plasminogen; inflammatory state
Statins (simvastatin and atorvastatin) Thrombin generation; inflammatory state
Aspirin  Acetylation of fibrinogen
Angiotensin converting enzyme inhibitors  Fibrinolysis
Vitamin K antagonists 
(warfarin, acenocoumarol)
Thrombin generation via vitamin K ‑dependent factors
Non –vitamin K antagonist oral anticoagulants 
(rivaroxaban, apixaban, dabigatran)
Thrombin generation by activated factor X or thrombin inhibition
Heparins Thrombin generation by activated factor X inhibition
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high between ‑laboratory variability of the meth‑
ods describing fibrin clot structure and function, 
the standardization of assays is highly required. 
A well‑trained technical staff with great hands‑
‑on experience can support this process; howev‑
er, still an automatization of manual methods is 
needed to reduce operator ‑related bias.23 Recently, 
we have developed a semiautomated device con‑
trolled by software to assess Ks quickly and pre‑
cisely after clot washing.23 Even though the clot 
preparation has to be conducted manually, our 
device allows for an analysis of additional pa‑
rameters describing clot structure and kinetics 
of buffer permeation through the fibrin mesh.23 
Such devices are needed to implement Ks mea‑
surements in clinical practice.
Concluding remarks Fibrin clot structure and 
function is involved in the pathogenesis and prog‑
nosis of thromboembolic events. Fibrin clots com‑
posed of compact, highly branched networks with 
thin fibers are resistant to lysis, and such prop‑
erties have been reported in patients with sever‑
al diseases with increased risk of thromboembo‑
lism. Recent data indicate that the prothrombot‑
ic fibrin phenotype assessed in plasma samples 
might be used as a prognostic marker in VTE and 
ischemic stroke related to AF. Further research 
is needed to better understand the role of fibrin 
properties in thromboembolism and implement 
these measures in clinical practice.
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